Acne Vulgaris is a common skin disorder marked by the appearance of pimples, blackheads, cysts, and nodules. While it predominantly affects adolescents, it can manifest at any age. The condition arises due to excessive sebum production and clogged hair follicles, which lead to inflammation. Although acne is generally not life-threatening, it can significantly affect an individual’s quality of life by causing psychological distress, scarring, and social stigma. Treatment mainly aims to reduce inflammation, bacterial load, and sebum secretion.

Explore key stats, market drivers, and emerging drugs—all in one visual!: Click Here

Acne Vulgaris Epidemiological Segmentation
The epidemiological segmentation of Acne Vulgaris in the 7MM from 2020 to 2034 covers:

• Total prevalent cases of Acne Vulgaris
  
• Total diagnosed prevalent cases of Acne Vulgaris
  
• Gender-specific diagnosed prevalent cases of Acne Vulgaris
  
• Severity-specific diagnosed prevalent cases of Acne Vulgaris
  
• Treatable cases of Acne Vulgaris
  

Acne Vulgaris Epidemiology
In 2023, around 140.2 million cases of Acne Vulgaris were reported across the 7MM, with approximately 69.5 million cases in the US alone. These figures are projected to increase over the forecast period.

In the 7MM, diagnosed cases were more common among females, accounting for 63% of the total diagnosed cases.

Regarding severity, Acne Vulgaris in the 7MM showed the following distribution:

• Moderate cases represented the largest share, comprising 45% of diagnosed cases.
  
• Severe cases were the least common, making up only 10% of total cases.

One graphic, all the essentials—click to explore!: Click Here

Acne Vulgaris Market
The total market value for Acne Vulgaris in the 7MM was estimated at around USD 4.26 billion in 2023.

Acne Vulgaris Market Drivers
The emergence of new treatments such as SB204, DMT310, and BTX 1503 is expected to expand therapy options by offering more targeted, effective, and safer treatments for Acne Vulgaris.

Increasing awareness of the disease, particularly regarding its psychological effects, along with enhanced diagnostic methods, is anticipated to stimulate growth in the Acne Vulgaris treatment market.

Acne Vulgaris Market Barriers
The variable presentation of Acne Vulgaris and differing responses to treatment, especially in moderate and severe cases, pose challenges to the development and approval of therapies, resulting in unpredictable treatment results.

Additionally, the high cost of treatments, especially newer, advanced options, and limited access to healthcare in some regions could impede market growth.

Acne Vulgaris Emerging Therapies

• SB204
  
• DMT310
  
• BTX 1503
  
• B244
  
• BPX-01
  
• And others
  

Acne Vulgaris Key Players

• Pelthos Therapeutics
  
• Dermata Therapeutics
  
• Botanix Pharmaceuticals
  
• AOBiome LLC
  
• BioPharmX
  
• Timber Pharmaceuticals
  
• And others

Grab your free copy of the infographic—essential for any analyst!: Click Here